Passage Bio, Inc. SEC filings document a clinical-stage genetic medicines issuer focused on PBFT02 for neurodegenerative diseases. Form 8-K reports cover financial results, Regulation FD presentations, PBFT02 clinical and regulatory updates, lease termination matters, and exit or disposal activity affecting operating costs.
Proxy materials disclose board composition, audit committee changes, executive compensation, and equity-award governance. The filing record also identifies the company's public reporting status, Delaware incorporation, Nasdaq listing venue, and recurring capital-resource disclosures tied to development-stage biotechnology operations.
Passage Bio’s latest quarter highlights shrinking resources, deep cost cuts, and mounting uncertainty. The company reported a Q1 2026 net loss of $7.6 million, improved from $15.4 million a year earlier as research and development and general and administrative expenses both declined.
Cash and cash equivalents fell to $33.3 million at March 31, 2026, and management concludes this will not cover capital needs for the next 12 months, raising “substantial doubt” about its ability to continue as a going concern. To preserve cash, Passage Bio terminated its Hopewell laboratory lease, paying a $4.8 million fee but recording a net gain on lease termination and sharply reducing lease liabilities.
After quarter-end, the company began reviewing strategic alternatives, including potential mergers, asset sales, or licensing deals, and announced a restructuring that will cut its workforce by about 75%, with estimated severance costs of $3.3 million. Passage Bio remains a clinical-stage biotech centered on lead gene therapy PBFT02 but is reassessing next steps in its development programs under these financial constraints.
Passage Bio, Inc. is launching a major restructuring as it continues to review strategic alternatives to maximize shareholder value. The company plans to cut its workforce by approximately 75% under a formal Restructuring Plan aimed at lowering operating expenses.
The restructuring is expected to be substantially complete in the second and third quarters of 2026. Impacted employees will be eligible for severance benefits, contingent on signing a severance agreement that includes a general release of claims. Passage Bio estimates aggregate severance and exit costs of about $3.3 million, primarily recorded in the second quarter of 2026, while cautioning that actual costs could differ and that additional expenses may arise from the restructuring and ongoing strategic review.
Passage Bio, Inc. reported updated interim data from its Phase 1/2 upliFT-D trial of PBFT02 for frontotemporal dementia with GRN mutations. Patients earlier in disease progression showed reduced brain atrophy and stabilized plasma NfL levels versus natural history, while more advanced patients did not show similar improvements.
The company completed a Type C meeting where the FDA indicated a randomized controlled registrational trial would be required for PBFT02 in FTD-GRN. Citing ethical, logistical, and financial challenges, Passage Bio is evaluating next steps for PBFT02 and the broader program.
Passage Bio also initiated a review of strategic alternatives that could include mergers, acquisitions, reverse merger, asset sales, partnerships, or licensing, and engaged Wedbush PacGrow as financial advisor. The company does not plan further updates until its board approves a specific action or disclosure is otherwise required.
Passage Bio, Inc. is holding its 2026 Annual Meeting of Stockholders as a virtual-only event on May 19, 2026 at 9:00 a.m. Eastern Time. Holders of 3,207,810 shares of common stock as of March 26, 2026 may vote.
Stockholders will vote on electing two Class III directors, ratifying KPMG LLP as independent auditor for 2026, approving on a non-binding advisory basis the compensation of named executive officers, and choosing how often to hold future advisory pay votes. The board recommends voting for both nominees, for KPMG, for executive pay, and for an annual say-on-pay vote.
The proxy also details governance practices, committee structures, director and executive pay, stock ownership of major holders and management, and change-in-control and severance protections for senior executives.
Passage BIO, Inc. reported that CFO Kathleen Borthwick received an employee stock option grant covering 15,610 shares of common stock. The option has an exercise price of $7.64 per share and expires on March 16, 2035.
The award vests as to 1/48 of the total shares each month beginning on April 16, 2026, so long as she continues providing service on each vesting date. Following this grant, she holds stock options for 15,610 shares directly.
Passage BIO, Inc. reported that President and CEO William Chou received a grant of employee stock options for 58,000 shares of common stock at an exercise price of $7.64 per share. The options vest in equal monthly installments over 48 months beginning on April 16, 2026 and expire on March 16, 2035. This grant is a compensation award, not an open-market purchase or sale, and leaves Chou holding 58,000 options following the transaction.
Passage Bio, Inc. entered into a lease termination agreement with Hopewell Campus Owner LLC on March 4, 2026, ending its lease for about 62,000 square feet of laboratory space in Hopewell. The lease, originally signed in December 2020, carried a 15‑year term starting in March 2021.
Under the termination agreement, Passage Bio will pay the landlord a termination fee of approximately $4.8 million plus accrued rent through February 14, 2026. The company had already ceased all operations at the Hopewell facilities following a restructuring in January 2025.
After this agreement, Passage Bio states it expects its cash and cash equivalents to fund operations through the first quarter of 2027, while cautioning that this estimate is based on assumptions that may change and could result in capital being used faster than anticipated.
Passage Bio files its annual report describing progress on PBFT02, a gene therapy for frontotemporal dementia caused by progranulin deficiency (FTD-GRN) and related neurodegenerative diseases. In a Phase 1/2 trial, Dose 1 of PBFT02 raised cerebrospinal fluid progranulin from below 3.0 ng/mL at baseline to means of 12.4 ng/mL at one month, 19.4 ng/mL at six months, 25.9 ng/mL at 12 months and 23.8 ng/mL at 18 months, above healthy control ranges. Plasma neurofilament light chain, a marker of neurodegeneration, increased 4% at 12 months versus natural-history increases of about 28–29%. Safety data showed treatment-related venous sinus thrombosis and hepatotoxicity at the higher dose, which were asymptomatic and responsive to treatment. The company is now enrolling a lower-dose Cohort 3, extending PBFT02 development into FTD with C9orf72 mutations, and positioning a higher-yield suspension manufacturing process with Catalent for late-stage trials. Passage Bio also highlights an HD program with Gemma Biotherapeutics targeting MSH3 to reduce somatic instability, plus orphan and Fast Track designations for PBFT02 in FTD.
Passage Bio reported fourth-quarter and full-year 2025 results and highlighted progress in its PBFT02 gene therapy program for frontotemporal dementia. The company enrolled the first three FTD-GRN patients in Cohort 3 and treated the first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4 of the upliFT-D study.
Net loss for 2025 was $45,522 thousand, narrowing from $64,767 thousand in 2024, as research and development expenses fell to $23,276 thousand from $40,179 thousand and general and administrative expenses declined to $19,875 thousand from $24,988 thousand. Cash and cash equivalents were $46,303 thousand at December 31, 2025, and the company projects a cash runway through the first quarter of 2027.
The upliFT-D Phase 1/2 trial continues to enroll FTD-GRN and FTD-C9orf72 patients, focusing primarily on safety and tolerability, with biomarker and clinical outcomes as secondary measures. Passage Bio plans updated interim safety and biomarker data and regulatory feedback on an FTD-GRN registrational trial design in the first half of 2026, and expects to select a clinical candidate for its Huntington’s program in the second half of 2026.